Published in Blood Weekly, September 2nd, 2004
Given orally once a day, the lead compound is a small molecule that acts directly on the blood coagulation enzyme Factor Xa, a clinically validated target involved in the generation of thrombin, the principal mediator of excessive clotting resulting in thrombosis.
Under the terms of the agreement, Portola has licensed exclusive rights to develop, market and commercialize Factor Xa inhibitors worldwide. Portola will make milestone and royalty payments to Millennium upon achievement of certain events.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.